Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents

ANGELERGUES, Antoine; EFSTATHIOU, Eleni; GYFTAKI, Revekka; WYSOCKI, Piotr; LAINEZ, Nuria; GONZALEZ, Iria; CASTELLANO, Daniel; Ozguroglu, Mustafa; GARCIA CARBONERO, Iciar; FLECHON, Aude; BORREGA, Pablo; GUILLOT, Aline; CAMPOS BALEA, Begona; LE MOULEC, Sylvestre; ESTEBAN, Emilio; MUNARRIZ, Javier; RUBIO, Gustavo; BIRTLE, Alison; DELANOY, Nicolas; BELLMUNT, Joaquim; OUDARD, Stephane

doi:10.1016/j.clgc.2018.02.016

Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents

ANGELERGUES A., EFSTATHIOU E., GYFTAKI R., WYSOCKI P. J., LAINEZ N., GONZALEZ I., ...Daha Fazla

CLINICAL GENITOURINARY CANCER, cilt.16, sa.4, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 16 Sayı: 4
Basım Tarihi: 2018
Doi Numarası: 10.1016/j.clgc.2018.02.016
Dergi Adı: CLINICAL GENITOURINARY CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
İstanbul Üniversitesi Adresli: Evet

Özet

Several agents have demonstrated an overall survival (OS) benefit in metastatic castration-resistant prostate cancer (mCRPC); however, optimal sequencing is unknown. Retrospective analysis of data from 574 mCRPC patients showed increasing OS with the number of therapies provided; a sequence including docetaxel, cabazitaxel (CABA), and an androgen receptor-targeted agent (ART) provided the greatest benefit. Prior administration of ART did not appear to influence CABA activity. These findings will help guide treatment decisions in daily practice.